摘要
目的观察蜈蚣败毒饮治疗寻常型银屑病血瘀证的临床疗效及对血脂、生长因子的影响。方法选取80例寻常型银屑病血瘀证患者,采用随机数字表法随机分为治疗组与对照组,每组40例,治疗组予口服蜈蚣败毒饮治疗,对照组予口服疗癣卡西甫丸合血府逐瘀丸治疗,疗程28d。比较治疗前后两组银屑病面积与严重性指数评分(PASI)、中医症候评分、社会相关生活质量指数评分(DLQI)、总胆固醇(TC)、三酰甘油(TG)、血管内皮生长因子(VEGF)、血小板衍生生长因子(PDGF)及安全性情况。结果与治疗前相较,两组PASI评分、中医症候评分、DLQI评分、TC、TG、VEGF、PDGF显著降低(P<0.05);与对照组相较,治疗组治疗后PASI评分、中医症候评分、DLQI评分、TC、TG、VEGF、PDGF显著降低(P<0.05);两组安全性差异无统计学意义(P>0.05)。结论蜈蚣败毒饮可有效改善患者皮损状况及症状,提高患者生活质量,具有较高的安全性,适合临床推广使用。
Objective To observe the clinical efficacy and the effect on blood lipids and growth factors of Wugong Baidu Decoc⁃tion in the treatment of blood stasis in common psoriasis.Methods Eighty patients with common psoriasis with blood stasis were selected and randomly divided into treatment group and control group by random number table method,40 patients in each group were treated with Wugong Baidu Decoction orally,while the control group was treated with Centipede Cachefu Pill combined with Blood Mansion and Blood Stasis Pill orally for 28 d.The psoriasis area and severity index score(PASI),Chinese medicine symp⁃tom score,social-related quality of life index(DLQI),total cholesterol(TC),triacylglycerol(TG),and blood lipids were compared between the two groups before and after treatment.The results were compared with those before and after treatment.Re⁃sults Compared with the pre-treatment group,PASI score,TCM symptom score,DLQI score,TC,TG,VEGF,and PDGF were significantly lower in both groups(P<0.05);compared with the control group,PASI score,TCM symptom score,DLQI score,TC,TG,VEGF,and PDGF were significantly lower in the treatment group(P<0.05);the difference in safety between the two groups was not statistically significant(P>0.05).Conclusion Wugong Baidu Decoction effectively improves patients'skin le⁃sion condition and symptoms,improves patients'quality of life,has a high safety level,and is suitable for clinical promotion and use.
作者
林丽
杨素清
任宇坤
安月鹏
LIN Li;YANG Su-qing;REN Yu-kun;AN Yue-peng(Heilongjiang University of Chinese Medicine,Harbin Heilongjiang 150040 China;First Affiliated Hospi-tal of Heilongjiang University of Chinese Medicine,Harbin Heilongjiang 150040 China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2023年第12期2945-2947,共3页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(81904201,81973846)
国家重点研发计划“中医药现代化研究”重点专项课题(2018YFC1705303)。
关键词
银屑病
蜈蚣败毒饮
血瘀证
血脂
生长因子
Psoriasis
Wugong Baidu Decoction
Blood stasis evidence
Blood lipids
Growth factor
